Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 19/20 | 0.49 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.42 |
| ▸ | CDK2 | P24941 | 6/20 | 0.42 |
| ▸ | CCNA1 | P78396 | 6/20 | 0.42 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | BCR | P11274 | 1/20 | 0.38 |
| ▸ | PLK1 | P53350 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.37 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.37 |
| ▸ | AURKC | Q9UQB9 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5446062 | 0.92 | AURKA (0.49) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5453857 | 0.91 | CDK2 (0.53) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5454355 | 0.90 | AURKA (0.51) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5456582 | 0.89 | AURKA (0.52) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5454404 | 0.87 | AURKA (0.49) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5451776 | 0.85 | GAA (0.36) | AURKACDK2 | |
| SCHEMBL5454239 | 0.83 | AURKA (0.51) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5451968 | 0.82 | PRKCB (0.44) | AURKACCNA2CDK2CCNA1FLT3 | |
| SCHEMBL5495916 | 0.82 | AURKA (0.55) | AURKACCNA2CDK2CCNA1AURKB | |
| SCHEMBL5451846 | 0.82 | CDK2 (0.50) | AURKACCNA2CDK2CCNA1AURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | claimed |
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K15, MAP3K7, MAP3K19 | AURKA 179/4885CCNA2 1123/4885CDK2 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.